Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJun 30, 2026
DataAggregated Company Financials
Companies183
  • 7D2.2%
  • 3M16.9%
  • 1Y11.3%
  • YTD13.7%

In the last week, the Pharma industry is up 2.2%, with Dr. Reddy's Laboratories up 4.3%. This takes the industry's 12 month performance to a gain of 11%. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 30 Jun 2026₹23.2t₹4.5t₹643.1b30.1x36.1x5.2x
Thu, 28 May 2026₹22.4t₹4.5t₹641.0b30x35x5x
Sat, 25 Apr 2026₹20.5t₹4.3t₹621.0b29.2x33x4.7x
Mon, 23 Mar 2026₹20.1t₹4.3t₹621.2b25.6x32.3x4.6x
Wed, 18 Feb 2026₹20.2t₹4.3t₹620.4b27x32.5x4.6x
Fri, 16 Jan 2026₹20.2t₹4.2t₹613.3b28.4x32.9x4.8x
Sun, 14 Dec 2025₹20.6t₹4.2t₹614.4b28.1x33.5x4.9x
Tue, 11 Nov 2025₹20.2t₹4.2t₹607.8b29.7x33.3x4.9x
Thu, 09 Oct 2025₹19.9t₹4.1t₹588.1b30.5x33.9x4.9x
Sat, 06 Sep 2025₹20.3t₹4.1t₹589.3b30x34.4x5x
Mon, 04 Aug 2025₹20.3t₹4.0t₹587.5b32.2x34.6x5x
Wed, 02 Jul 2025₹20.4t₹4.0t₹595.4b33.6x34.3x5.1x
Fri, 30 May 2025₹20.0t₹4.0t₹592.7b32.3x33.7x5x
Sun, 27 Apr 2025₹19.5t₹3.9t₹560.8b30x34.9x5x
Tue, 25 Mar 2025₹19.9t₹3.9t₹559.4b29.9x35.5x5.1x
Thu, 20 Feb 2025₹18.9t₹3.9t₹560.1b28.5x33.8x4.9x
Sat, 18 Jan 2025₹20.2t₹3.8t₹527.1b32.4x38.2x5.3x
Mon, 16 Dec 2024₹20.6t₹3.8t₹526.7b35.2x39x5.4x
Wed, 13 Nov 2024₹20.5t₹3.8t₹513.3b36.2x39.9x5.4x
Fri, 11 Oct 2024₹21.5t₹3.7t₹492.6b41.6x43.6x5.8x
Sun, 08 Sep 2024₹21.3t₹3.7t₹492.4b41.9x43.3x5.7x
Tue, 06 Aug 2024₹19.7t₹3.7t₹472.1b35.6x41.7x5.3x
Thu, 04 Jul 2024₹17.8t₹3.6t₹448.3b33.2x39.7x5x
Sat, 01 Jun 2024₹16.8t₹3.6t₹452.1b32.1x37.1x4.7x
Mon, 29 Apr 2024₹17.0t₹3.5t₹418.3b34.6x40.6x4.9x
Wed, 27 Mar 2024₹16.8t₹3.5t₹418.7b32x40.1x4.8x
Fri, 23 Feb 2024₹17.0t₹3.5t₹418.6b34.2x40.7x4.9x
Sun, 21 Jan 2024₹15.7t₹3.4t₹395.3b35x39.8x4.6x
Tue, 19 Dec 2023₹14.5t₹3.4t₹395.2b32.3x36.6x4.3x
Thu, 16 Nov 2023₹13.7t₹3.4t₹399.0b30.8x34.4x4.1x
Sat, 14 Oct 2023₹13.2t₹3.3t₹369.9b30x35.6x4x
Mon, 11 Sep 2023₹13.1t₹3.3t₹369.5b30.3x35.5x4x
Wed, 09 Aug 2023₹13.2t₹3.2t₹356.8b29.7x36.9x4.1x
Fri, 07 Jul 2023₹11.8t₹3.2t₹342.4b26.5x34.4x3.7x
Price to Earnings Ratio

34.4x


Total Market Cap: ₹11.8tTotal Earnings: ₹342.4bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-1.47%
Healthcare1.41%
Pharma2.18%
Pharma2.18%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
500124 Dr. Reddy's Laboratories₹1.36k4.3%
+₹46.3b		6.3%PE26.4x
500420 Torrent Pharmaceuticals₹4.62k2.4%
+₹36.7b		35.3%PE72.3x
GLAND Gland Pharma₹2.50k8.6%
+₹32.4b		32.9%PE40x
AJANTPHARM Ajanta Pharma₹3.42k7.4%
+₹29.4b		36.8%PE40.5x
500257 Lupin₹2.42k2.7%
+₹29.1b		23.4%PE20.7x

Latest News

SUNPHARMA
₹1,862.50
Sun Pharmaceutical Industries
7D
-0.3%
1Y
11.7%
CONCORDBIO
₹1,280.20
Concord Biotech
7D
-2.9%
1Y
-28.7%
New Narrative • Jun 29

Injectable Capacity And Diversified Platforms Will Drive Strong Long-Term Potential

Catalysts About Concord Biotech Concord Biotech is a fermentation based biopharma company focused on active pharmaceutical ingredients and formulations in areas such as immunosuppressants, anti infectives and oncology. What are the underlying business or industry changes driving this perspective?
SANOFICONR
₹4,597.00
Sanofi Consumer Healthcare India
7D
-2.8%
1Y
-15.2%
500257
₹2,420.15
Lupin
7D
2.7%
1Y
23.4%
CIPLA
₹1,465.40
Cipla
7D
2.3%
1Y
-3.3%
AUROPHARMA
₹1,578.70
Aurobindo Pharma
7D
2.9%
1Y
39.4%
500124
₹1,356.85
Dr. Reddy's Laboratories
7D
4.3%
1Y
6.3%
Narrative Update • Jun 25

500124: Lower Profitability Expectations Will Restrain Future Share Price Upside

Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.
500420
₹4,622.60
Torrent Pharmaceuticals
7D
2.4%
1Y
35.3%
Narrative Update • Jun 25

500420: Dividend Payouts And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their fair value estimate for Torrent Pharmaceuticals steady at about ₹4,878.79 per share, citing unchanged assumptions for revenue growth, profit margins, discount rate, and future P/E multiple. What's in the News for Torrent Pharmaceuticals At its AGM on 23 June 2026, Torrent Pharmaceuticals declared a final dividend of ₹9.00 per equity share of face value ₹5.00 for the financial year ended 31 March 2026.
GLAND
₹2,495.00
Gland Pharma
7D
8.6%
1Y
32.9%
Narrative Update • Jun 24

GLAND: US Injectable Approvals And Dividend Will Support Future Rerating

Analysts have kept their ₹2,645 price target on Gland Pharma unchanged, citing relatively steady assumptions around revenue growth, profit margins and future P/E multiples in their updated model. What’s in the News for Gland Pharma The U.S. FDA approved Apotex, Orbicular and Gland Pharma’s Abbreviated New Drug Application for generic Infuvite Pediatric Injection.
ACUTAAS
₹3,526.20
Acutaas Chemicals
7D
7.6%
1Y
214.3%
Narrative Update • Jun 24

ACUTAAS: Rich Future P E And Dividend Plans Will Pressure Returns

Analysts have trimmed their fair value estimate for Acutaas Chemicals, with the price target moving from ₹2,486.33 to ₹2,390.78. This reflects updated assumptions around future P/E while keeping growth and margin expectations broadly unchanged.
ERIS
₹1,433.50
Eris Lifesciences
7D
-1.9%
1Y
-14.5%
Narrative Update • Jun 22

ERIS: Stable Outlook And Upcoming Board Decisions Will Drive Future Upside

Analysts have kept their fair value estimate for Eris Lifesciences steady at ₹1,696.60, with only minor model adjustments to profit margin assumptions and forward P/E inputs informing this unchanged price target. What’s in the News for Eris Lifesciences Eris Lifesciences has scheduled a board meeting on May 20, 2026 to consider and approve standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
AJANTPHARM
₹3,422.70
Ajanta Pharma
7D
7.4%
1Y
36.8%
WOCKPHARMA
₹1,941.40
Wockhardt
7D
-3.4%
1Y
15.7%
AARTIPHARM
₹680.05
Aarti Pharmalabs
7D
-4.3%
1Y
-25.5%
New Narrative • Jun 01

CDMO Expansion And Xanthine Capacity Will Support Long Term Earnings Resilience

Catalysts About Aarti Pharmalabs Aarti Pharmalabs is a pharmaceutical manufacturer active in xanthine derivatives, APIs and intermediates, and contract development and manufacturing services. What are the underlying business or industry changes driving this perspective?
506820
₹8,216.00
AstraZeneca Pharma India
7D
-3.4%
1Y
-7.7%
500488
₹25,436.80
Abbott India
7D
-0.5%
1Y
-26.7%